Legend Biotech (LEGN) Gets a Buy Rating from BTIG

In a report issued on March 11, Justin Zelin from BTIG maintained a Buy rating on Legend Biotech (LEGNResearch Report), with a price target of $75.00. The company’s shares closed last Friday at $38.53.

According to, Zelin has 0 stars on 0-5 stars ranking scale with an average return of -11.9% and a 30.5% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Poseida Therapeutics, Viking Therapeutics, and Surface Oncology.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Legend Biotech with a $63.75 average price target, representing a 63.3% upside. In a report issued on March 15, Barclays also initiated coverage with a Buy rating on the stock with a $53.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Legend Biotech’s market cap is currently $5.89B and has a P/E ratio of -14.99.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm’s lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Its other pipeline products include LB1910, LB1909, LB1903, and others. Geographically, the company generates a majority of its revenue from North America.

Read More on LEGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More